🏛️ Verified NIH Record • Updated 2026-08-18
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis (NCT06832618)
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Incyte Corporation
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Center of Alabama — Birmingham, Alabama
Age range: 6 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (93 Sites)
Showing the first 25 of 93 sites.
- Clinical Research Center of Alabama — Birmingham, Alabama
- Saguaro Dermatology — Phoenix, Arizona
- National Jewish Health — Denver, Colorado
- Encore Medical Research, Llc Hollywood — Hollywood, Florida
- Lane Dermatology and Dermatologic Surgery — Columbus, Georgia
- Cleaver Medical Group — Cumming, Georgia
- Treasure Valley Medical Research — Boise, Idaho
- Sneeze Wheeze and Itch Associates Llc — Normal, Illinois
- Endeavor Health Medical Group — Skokie, Illinois
- Raven Clinical Research — Marriottsville, Maryland
- Oakland Hills Dermatology Pc — Auburn Hills, Michigan
- Henry Ford Health System — Detroit, Michigan
- University of Mississippi Medical Center — Jackson, Mississippi
- Red River Research Partners — Bolivar, Missouri
- Medisearch Clinical Trials — Saint Joseph, Missouri
- University of Rochester Medical Center — Rochester, New York
- Cincinnati Childrens Hospital Medical Center — Cincinnati, Ohio
- University of Texas Physicians - Bellaire Station — Bellaire, Texas
- Frontier Dermatology — Mill Creek, Washington
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Cliniques Universitaires Ucl Saint-Luc — Brussels,
- Az Sint-Lucas — Ghent,
- Universitair Ziekenhuis Gent — Ghent,
- Grand Hôpital de Charleroi-Les Viviers — Gilly,
- Centre Hospitalier Universitaire de Liege - Sart Tilman — Liège,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.